Group 1 - The year 2026 is positioned as a pivotal moment for the biopharmaceutical industry, marking the end of the "14th Five-Year Plan" and the beginning of the "15th Five-Year Plan," with a focus on balancing technological innovation and value-driven growth [1] - AI is expected to be a core driver of innovation in the healthcare sector, fundamentally changing service models and industry structures, as highlighted by experts like Wang Yuedan [1][5] - The integration of AI in daily health management is becoming prevalent, with approximately 60% of individuals consulting AI for minor health issues, reflecting the increasing accuracy and capabilities of AI systems [3] Group 2 - AI systems have shown significant improvements in diagnostic accuracy, with the ability to diagnose lung infections increasing from 78% to 92%, while the independent diagnostic capabilities of interns have decreased by 15% [3] - The development of wearable health devices is crucial for AI healthcare systems, with advancements in non-invasive and real-time monitoring becoming essential for health management and disease prediction [4] - AI research robots are increasingly replacing human researchers in biomedical fields, demonstrating strong capabilities in multi-omics data integration and analysis, which aids in personalized treatment design [6] Group 3 - The application of AI in healthcare is expected to expand in both basic disease management and advanced personalized treatments, establishing AI as a central figure in connecting biomedical research with clinical applications [7] - The future of healthcare will see AI playing a dual role in enhancing both general health management and high-end personalized treatment development, fundamentally altering the healthcare service landscape [7]